Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares of Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $81.11, for a total transaction of $1,622,200.00. Following the completion of the sale, the chief executive officer directly owned 1,192,987 shares of the company’s stock, valued at approximately $96,763,175.57. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.38, for a total value of $1,507,600.00.
• On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.01, for a total value of $3,000,400.00.
• On Thursday, November 13th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $63.01, for a total value of $1,260,200.00.

Apogee Therapeutics Trading Up 0.0%

Shares of Apogee Therapeutics stock opened at $80.77 on Friday. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $84.56. The firm has a market capitalization of $5.52 billion, a P/E ratio of -18.44 and a beta of 1.41. The business has a fifty day simple moving average of $73.44 and a two-hundred day simple moving average of $53.12.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.03. Analysts predict that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 7th. BTIG Research set a $137.00 price target on Apogee Therapeutics in a research report on Tuesday, January 6th. Royal Bank Of Canada reissued an “outperform” rating on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Wall Street Zen cut shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Finally, Mizuho started coverage on shares of Apogee Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $105.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in APGE. Lisanti Capital Growth LLC purchased a new position in shares of Apogee Therapeutics in the 2nd quarter worth $800,000. Fox Run Management L.L.C. purchased a new stake in Apogee Therapeutics during the second quarter valued at $437,000. Allspring Global Investments Holdings LLC bought a new position in Apogee Therapeutics in the second quarter valued at about $218,000. Prudential Financial Inc. boosted its position in Apogee Therapeutics by 176.4% in the second quarter. Prudential Financial Inc. now owns 68,845 shares of the company’s stock worth $2,990,000 after purchasing an additional 43,940 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Apogee Therapeutics in the third quarter worth about $5,333,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.